EGRX 0.9 (-54.77%)
US2697961082Drug ManufacturersDrug Manufacturers - Specialty & Generic

Eagle Pharmaceuticals (EGRX) Financial Metrics

This table shows a selected set of financial data points of Eagle Pharmaceuticals (EGRX). You can choose which elements to display by selecting the desired chart and column.

MarketCap

Total Revenue

Free CashFlow

Year EPS Dividend Yield PE Ratio MarketCap Return On Assets Total Revenue Free CashFlow EBITDA Net Income Cash
2022 2.76 0 10.61 378.06M 0.11 316.61M 50.52M 77.5M 35.64M 55.32M
2021 -0.66 0 -77.03 664.56M -0.03 171.55M 27.9M 847K -8.63M 97.66M
2020 0.89 0 52.37 627.83M 0.05 187.8M 48.75M 28.79M 11.99M 103.16M
2019 1.04 0 57.74 826.37M 0.06 195.89M 55.21M 28.18M 14.31M 109.78M
2018 2.09 0 19.3 615.58M 0.13 213.31M 52.25M 40.44M 31.9M 78.79M
2017 3.27 0 16.36 849.82M 0.21 236.71M 53.73M 77.83M 51.94M 114.66M
2016 4.96 0 16.01 1.3B 0.48 189.48M 32.52M 55.02M 81.45M 52.82M
2015 0.16 0 560.49 1.44B 0.03 66.23M -11.6M 2.7M 2.57M 79.08M
2014 -1.81 0 -8.58 154.32M -0.5 19.1M -13.89M -19.16M -17.98M 22.72M
2013 -0.63 0 0 0 -0.44 13.68M -5.92M -5.41M -6.05M 10.46M
2012 -1.83 0 0 0 0 2.54M -15.58M -19.62M -19.38M 5.07M

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.